A Study to Investigate the Safety, Tolerability and Pharmacokinetics of ABY-035

PHASE1CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

February 29, 2016

Primary Completion Date

January 10, 2018

Study Completion Date

January 10, 2018

Conditions
PsoriasisHealthy Subjects
Interventions
DRUG

Placebo

Single dose i.v.

DRUG

ABY-035 i.v.

Single dose i.v.

DRUG

ABY-035 s.c.

Single dose s.c.

Trial Locations (4)

LS2 9LH

Covance Clinical Research Unit Ltd., Leeds

L7 8XP

Covance and Royal Liverpool University Hospital Clinical Research Unit, Liverpool

W12 0HS

Imperial Centre for Translational and Experimental Medicine Imperial College Healthcare NHS Trust Hammersmith Hospital, London

M23 9QZ

Medicines Evaluation Unit Ltd, Manchester

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Covance

INDUSTRY

lead

Affibody

INDUSTRY